Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic opportunities for the treatment of NASH with genetically validated targets.

Journal of hepatology - 1 Oct 2023

Lindén Daniel, Romeo Stefano

Abstract excerpt

The identification of genetic variants associated with fatty liver disease (FLD) from genome-wide association studies started in 2008 when single nucleotide polymorphisms in PNPLA3, the gene encoding patatin-like phospholipase domain-containing 3, were found to be associated with altered hepatic fat content. Since then, several genetic variants associated with protection from, or an increased risk of, FLD have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diet, Metabolism, and Disease
Share to Endoplasmic Reticulum Stress and Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Genome-Wide Association Study

Share to Liver Disease Diagnosis and Treatment

Share to Non-alcoholic Fatty Liver Disease

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 37207913
DOI: 10.1016/j.jhep.2023.05.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic opportunities for the treatment of NASH with genetically validated targets.PMID 37207913Read ↗

PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date.Semantic proximity Read ↗

PNPLA3—A Potential Therapeutic Target for Personalized Treatment of Chronic Liver DiseaseSemantic proximity Read ↗

Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease.Semantic proximity Read ↗

Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation.Semantic proximity Read ↗

Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and TherapeuticsSemantic proximity Read ↗

Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis.Semantic proximity Read ↗

Advances in the genetics of nonalcoholic fatty liver disease.Semantic proximity Read ↗

Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis.Semantic proximity Read ↗

PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver diseaseSemantic proximity Read ↗

Discovery and Targeting of the Signaling Controls of PNPLA3 to Effectively Reduce Transcription, Expression, and Function in Pre-Clinical NAFLD/NASH SettingsSemantic proximity Read ↗

Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease.Semantic proximity Read ↗

PNPLA3 in Alcohol-Related Liver Disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.